Diabetes Stocks Remain Healthy There are nearly 133 million Americans alone considered overweight- putting them at risk for the rapidly growing Type II Diabetes.I have done a bit of research on projections as to how many Americans would be living with the disease in...
Pharmaceutical Pricing and Distribution in Japan Incorporates All Pricing Rule Changes That Came into Effect f 4:10 PM ET DUBLIN, Ireland--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/b2dd9e/pharmaceutical_pri) has announced the addition of the 'Pharmaceutical Pricing and Distribution in Japan: The keys to...
Pharmaceutical Pricing and Distribution in Japan Incorporates All Pricing Rule Changes That Came into Effect f DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/b2dd9e/pharmaceutical_pri) has announced the addition of the 'Pharmaceutical Pricing and Distribution in Japan: The keys to success in the...
ADA: Pramlintide May Be Better Choice than Insulin as Mealtime Diabetes Add-on Drug SAN FRANCISCO, June 12 -- For diabetic patients recently started on long-acting insulin, mealtime pramlintide (Symlin) may boost blood sugar control similar to rapid-acting insulin but with fewer side effects, researchers found.The drug...
Would You Cure A Profitable Disease? This article was originally published in Diabetes Health in October, 2003.People in the diabetes community, desperate for a cure, sometimes express considerable paranoia about the goals of the pharmaceutical industry.
After all, with ...
Five-Year Safety Study Examines the Effect of LANTUS on the Progression of Retinopathy in People with Type 2 A five-year safety study designed to assess the risk of exacerbation of diabetes-related retinopathy in patients with type 2 diabetes treated with LANTUS (insulin glargine [rDNA origin] injection) showed similar progression of...
New study calls for prompt insulin treatment on failure of diet, exercise & oral diabetes medications Results from a new study presented at the American Diabetes Association's (ADA) 68th Annual Scientific Sessions reinforce the importance of promptly initiating insulin treatment when patients with type 2 diabetes are unable to achieve...
Five-Year Safety Study Examines the Effect of LANTUS on the Progression of Retinopathy in People with Type 2 A five-year safety study designed to assess the risk of exacerbation of diabetes-related retinopathy in patients with type 2 diabetes treated with LANTUS (insulin glargine [rDNA origin] injection) showed similar progression of...
::: Insulin Glulisine APIDRA efficacy in the treatment of children and adolescents with type 1 diabetes - A new study comparing efficacy and safety of A RA and insulin Lispro as part of a basal-bolus regimen -Paris, France - June 7, 2008 - Sanofi-aventis announced today that A RA was shown to be non inferior to insulin lispro in term of...
ADA: Exenatide Doesn't Reverse Diabetes' Effects Durably SAN FRANCISCO, June 9 -- Beta-cell function improvements with the incretin mimetic exenatide (Byetta) are not lasting after treatment ends, Dutch researchers found.When exenatide was discontinued after a year of treatment among type 2...
Novo-Nordisk says Levemir insulin as effective as glargine over 24 hours period SAN FRANCISCO (Thomson Finacial) - Novo-Nordisk AS said a head-to-head study demonstrated that Levemir (insulin detemir) can be used once-daily and had a comparable blood glucose response to insulin glargine, the active ingredient in Sanofi...
Novo-Nordisk says Levemir insulin as effective as glargine over 24 hours period SAN FRANCISCO (Thomson Finacial) - Novo-Nordisk AS said a head-to-head study demonstrated that Levemir (insulin detemir) can be used once-daily and had a comparable blood glucose response to insulin glargine, the active ingredient in Sanofi...
Novo-Nordisk says Levemir insulin as effective as glargine over 24 hours period SAN FRANCISCO (Thomson Finacial) - Novo-Nordisk AS said a head-to-head study demonstrated that Levemir (insulin detemir) can be used once-daily and had a comparable blood glucose response to insulin glargine, the active ingredient in Sanofi...
Novo-Nordisk says Levemir insulin as effective as glargine over 24 hours period SAN FRANCISCO (Thomson Finacial) - Novo-Nordisk AS said a head-to-head study demonstrated that Levemir (insulin detemir) can be used once-daily and had a comparable blood glucose response to insulin glargine, the active ingredient in Sanofi...
Sanofi-Aventis says Lantus injection Helps Type 2 Diabetes patients reach the ADA's Recommended Target for Blo (RTTNews) - Sanofi-Aventis (SNY), a provider of health care products worldwide, presented on Saturday results from a new study that show the importance of promptly initiating insulin treatment when patients with type 2 diabetes are unable to...
Sanofi-Aventis says Lantus injection Helps Type 2 Diabetes patients reach the ADA's Recommended Target for Blo (RTTNews) - Sanofi-Aventis (SNY: News, Chart, Quote ), a provider of health care products worldwide, presented on Saturday results from a new study that show the importance of promptly initiating insulin treatment when patients with type 2...
Insulin Glulisine APIDRA efficacy in the treatment of children and adolescents with type 1 diabetes Abstract 1791-P Insulin Glulisine A RA efficacy in the treatment of children and adolescents with type 1 diabetes - A new study comparing efficacy and safety of A RA and insulin Lispro as part of a basal -bolus regimen Paris, France June 7,...
Novo Nordisk's FlexPen superior to SoloStar in dose accuracy: study Novo Nordisk's FlexiPen has proved its superiority over SoloStar, from Sanofi-Aventis, according to two independent studies.FlexPen is more accurate when delivering insulin than other pens like the newly launched prefilled device,...
Aventis Pharma set to launch new insulin pen in India by September Aventis Pharma Ltd, Indian arm of the Paris-based Sanofi Aventis, is all set to launch a new disposable insulin pen, Apidera, in the Indian market by September this year.Aventis, which has recently launched the pre-filled disposable...
Sanofi-aventis launches SoloSTAR insulin pen in India Aventis Pharma, belonging to world's third largest pharmaceutical company Sanof-Aventis of France, has launched a new prefilled disposable insulin pen, SoloSTAR for use with the 24-hour insulin Lantus. This disposable insulin pen is...
STOCKWATCH Sanofi treads water as Saredutant delays, unchanged guidance weigh PARIS (Thomson Financial) - Shares in Sanofi-Aventis edged lower on Wednesday morning, as delays to key pipeline drug Saretudant and unchanged full-year guidance, despite a consensus-beating first quarter, sparked concerns about the group's...
STOCKWATCH Sanofi Q1 profit beats consensus, but Saredutant delays may weigh PARIS (Thomson Financial) - Investors are expected to welcome Sanofi-Aventis's consensus-beating first quarter results Wednesday morning, but gains may be capped by concerns over delays to the group's key pipeline antidepressant Saredutant....
